

Laura Niccoli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1996838/publications.pdf>

Version: 2024-02-01

16
papers

1,060
citations

840776

11
h-index

996975

15
g-index

16
all docs

16
docs citations

16
times ranked

2412
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. <i>Journal of Infection</i> , 2020, 81, 318-356. | 3.3 | 358 |
| 2 | Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study. <i>Journal of Infection</i> , 2020, 81, 647-679. | 3.3 | 155 |
| 3 | Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics. <i>Mediators of Inflammation</i> , 2017, 2017, 1-15. | 3.0 | 93 |
| 4 | Psoriatic arthritis: a systematic review. <i>International Journal of Rheumatic Diseases</i> , 2010, 13, 300-317. | 1.9 | 91 |
| 5 | Adalimumab, Etanercept, Infliximab, and the Risk of Tuberculosis: Data from Clinical Trials, National Registries, and Postmarketing Surveillance. <i>Journal of rheumatology Supplement, The</i> , 2014, 91, 47-55. | 2.2 | 89 |
| 6 | Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review. <i>Drugs</i> , 2020, 80, 1929-1946. | 10.9 | 74 |
| 7 | Frequency of iridocyclitis in patients with early psoriatic arthritis: a prospective, follow up study. <i>International Journal of Rheumatic Diseases</i> , 2012, 15, 414-418. | 1.9 | 54 |
| 8 | Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 501-512. | 4.4 | 53 |
| 9 | Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 415-425. | 2.4 | 33 |
| 10 | Systematic review on tuberculosis risk in patients with rheumatoid arthritis receiving inhibitors of Janus Kinases. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 861-872. | 2.4 | 24 |
| 11 | Rapid loss of efficacy of biosimilar infliximab in three patients with Behçet's disease after switching from infliximab originator. <i>European Journal of Rheumatology</i> , 2017, 4, 288-290. | 0.6 | 22 |
| 12 | <p>Therapeutic Potential of Ixekizumab in the Treatment of Ankylosing Spondylitis: A Review on the Emerging Clinical Data</p>. <i>Therapeutics and Clinical Risk Management</i> , 2020, Volume 16, 287-297. | 2.0 | 4 |
| 13 | Bioboosters in the treatment of rheumatic diseases: a comprehensive review of currently available biologics in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. <i>Open Access Rheumatology: Research and Reviews</i> , 2009, 1, 163. | 1.6 | 3 |
| 14 | Biosimilars for the treatment of psoriatic arthritis. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 1195-1203. | 3.0 | 3 |
| 15 | Tailored first-line biologic and targeted synthetic disease modifying anti-rheumatic drugs therapy in patients with rheumatoid arthritis: 2021 updated ITABIO statements. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 613-623. | 2.4 | 3 |
| 16 | The Nocebo Effect in Rheumatology: An Unexplored Issue. <i>Israel Medical Association Journal</i> , 2020, 22, 185-190. | 0.1 | 1 |